Jim Cramer: This Health Care Stock Is Pure Spec, The Only Neocloud I Like Is...
Cramer calls Nuvation Bio a pure spec, prefers CoreWeave over IREN, is unsure on Seneca, cautious on NuScale, and approves Box.
Stocks · News reference
Box Lowers FY2027 Adj EPS Guidance from $1.56 to $1.54 vs $1.58 Est; Raises FY2027 Sales Guidance from $1.280B to $1.290B vs $1.281B Est
Box (NYSE:BOX) lowers FY2027 Adj EPS guidance from $1.56 to $1.54 vs $1.58 analyst estimate. Raises FY2027 sales outlook from $1.280 billion to $1.290 billion vs $1.281 billion estimate.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Why Box Stock Ticked Higher on Wednesday
Box stock rose 1.18% on Wednesday following second-quarter earnings that met expectations. The company reported record revenue of $321 million (up 9% YoY) and adjusted net income of $0.40 per share. Box raised full-year revenue guidance to $1.29 billion but slightly lowered profitability guidance to $1.54 per share. Growth was driven by adoption of the Enterprise Advanced plan as clients scale AI capabilities.
Morgan Stanley Maintains Equal-Weight on Box, Raises Price Target to $36
Morgan Stanley analyst Josh Baer maintains Box (NYSE:BOX) with a Equal-Weight and raises the price target from $33 to $36.
Citigroup Maintains Buy on Box, Raises Price Target to $40
Citigroup analyst Steven Enders maintains Box (NYSE:BOX) with a Buy and raises the price target from $37 to $40.